Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain

GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.